1	Artificial intelligence-assisted meta-analysis of the frequency of ACE I/D
2	polymorphisms in centenarians and other long-lived individuals
3	
4	Lingxuan Li and Shin Murakami*
5	
6	Department of Basic Sciences, College of Osteopathic Medicine, Touro University California, Vallejo, CA
7 8	94592.
9	*, Corresponding author, Shin Murakami, PHD, FGSA
10	
11	
12	Abstract
13	
14	Current research on the angiotensin-converting-enzyme (ACE) gene has yielded controversial
15	results on whether different ACE polymorphisms are linked with human longevity. ACE
16	polymorphisms are a risk factor for Alzheimer's disease and age-onset diseases that may
17	contribute to the mortality of older people. Our goal is to consolidate existing studies with
18	assistance from artificial intelligence and machine-learning-assisted software to come to a more
19	precise understanding of the role of the ACE gene in human longevity. The I (insertion) and D
20	(deletion) polymorphisms in the intron are correlated with the levels of circulating ACE;
21	homozygous D (DD) is high and homozygous I (II) is low. Here, we performed a detailed meta-
22	analysis of the I and D polymorphisms using centenarians (100+ years old), long-lived subjects
23	(85+ years old), and control groups. ACE genotype distribution was analyzed across a total of
24	2,054 centenarians and 12,074 controls, as well as 1,367 long-lived subjects between the ages
25	of 85-99, using the inverse variance and random effects methods. The ACE DD genotype was
26	found to be favored in centenarians (OR: 1.41 [95% CI: 1.19-1.67], P < 0.0001) with a
27	heterogeneity of 32%, and the II genotype slightly favored the control groups (OR: 0.81 [95% CI:
28	0.66-0.98], P = 0.03) with a heterogeneity of 28%, corroborating results from previous meta-
29	analyses. Novel to our meta-analysis, the ID genotype was found to be favored in control
30	groups (OR: 0.86 [95% CI: 0.76-0.97], $P = 0.01$ ) with a heterogeneity of 0%. The long-lived group
31	showed a similar positive association between the DD genotype and longevity (OR: 1.34 [95%
32 33	CI: 1.21-1.48, P < 0.0001) and a negative association between the II genotype and longevity (OR: 0.79 [95% CI: 0.70-0.88], P < 0.0001). The long-lived ID genotype did not show significant
33 34	findings (OR: 0.93 [95% CI: 0.84-1.02], $P = 0.79$ ). In conclusion, the results suggest a significant
35 35	positive association of the DD genotype with human longevity. However, despite the previous
36	study, the results do not confirm a positive association of the ID genotype with human
37	longevity. We suggest a few paradoxical observations: (1) inhibition of ACE can increase
38	longevity in model systems from nematodes to mammals, seemingly opposite to the finding in
39	humans; (2) exceptional longevity associated with homozygous DD is also associated age-
40	related diseases with higher mortality risks in homozygous DD. We discuss ACE, longevity, and
41	age-related diseases.
42	
43	Introduction

It is made available under a CC-BY 4.0 International license .

Human life expectancy has increased in the past millennia since the studies of longevity in 45 ancient Greek and Roman populations (Montagu, 1994; Batrinos, 2008; Roser et al., 2013). The 46 47 study of aging, including the biology of aging and populations of older people, has suggested that longevity is influenced by a combination of genetic, lifestyle, and environmental factors 48 49 (reviewed in Weinert et al., 2003). The search for genetic causes of longevity has implicated 50 several possible candidate genes, including SIRT1, APOE, FOXO3A, ACE, ATM, NOS1, NOS2, KLOTHO and IL6 (reviewed in Revelas et al., 2018; Costa et al., 2019). Of them, ACE encodes an 51 angiotensin-converting enzyme, which has two functions with opposing effects on health (Duc 52 et al., 2020; Duc et al., 2021). Firstly, ACE is an essential enzyme for hemodynamic control via 53 the renin-angiotensin-aldosterone system and the kinin-kallikrein system. ACE converts the 54 55 inactive angiotensin I to the active angiotensin II, a potent vasoconstrictor, and inactivates 56 bradykinin, a potent vasodilator. ACE inhibitors are one of the first-line treatments for hypertension and congestive heart failure. In this function, ACE inhibition is beneficial to health 57 through controlling hypertension. Secondly, ACE is an amyloid-degrading enzyme that can 58 59 reduce the proteo-toxicity of amyloid. Importantly, ACE, when altered, is a risk factor gene in 60 Alzheimer's disease (Vahdati Nia et al., 2017; Murakami and Lacayo, 2022). ACE alterations are 61 associated with Alzheimer's disease (discussed in Duc et al., 2021). In this function, ACE inhibition may be deleterious to the health through amyloid toxicity. Thus, the effect of ACE on 62 longevity may differ depending on the health conditions of advanced aging (Duc et al., 2021). 63 Thus, we reason that long-lived groups should be included in this study. 64 65 The ACE gene is located on chromosome 17g23. The ACE I/D polymorphisms were first 66

identified in 1990, which are characterized by the presence (insertion, I) or absence (deletion, 67 68 D) of a 287-bp (base pair) Alu repeat sequence in intron 16 (Rigat et al., 1990). The I/D polymorphisms correlated with the serum levels of circulating ACE; the D-allele is higher and 69 70 the I-allele is lower (Tiret et al., 1992). The DD individuals have approximately twice the plasma 71 ACE levels as the II individuals do (Rigat et al., 1990; Tomita et al., 1996). Other meta-analyses 72 have also shown a positive association between the D-allele and increased risk of essential 73 hypertension (Li et al., 2011), ischemic stroke (Zhang et al., 2012), coronary artery disease 74 (Zintzaras et al., 2008), left ventricular hypertrophy (Li et al., 2012) and pneumonia (Nie et al., 2014). In addition, the D-allele has been linked with higher mortality rates from COVID-19 75 (Yamamoto et al., 2020). 76

77

78 Paradoxically, the ACE D allele is associated with the risk of cardiovascular disease,

79 hypertension, Alzheimer's disease, and other common causes of death in older people, while a

80 previous study noted an increased frequency of the DD genotype among a group of

centenarians from France (Schachter et al., 1994). Since then, centenarian studies have been

82 performed across different cohorts, resulting in conflicting results. A more recent study

suggests that the DD genotype and the D allele are enriched in centenarians (Garatachea et al.,

2013), while another study suggests that no significant difference among the I and D alleles

85 (Choi et a., 2003; Oscanoa, et al., 2020). In this meta-analysis, we further consolidated these

86 findings to more precisely determine whether or not the D polymorphism is enriched in

87 centenarians and long-lived individuals.

It is made available under a CC-BY 4.0 International license .

89

## 90 Methods

91

## 92 Nomenclature, PRISMA and Database search

93

94 Due to nomenclature inconsistency among studies, we used I (Insertion) and D (deletion) alleles 95 as follows: The genotypes were referred to as homozygous insertion (II), heterozygous insertion/deletion (ID), and homozygous deletion (DD). The I and D polymorphisms were 96 referred to as I/D. We followed the Preferred Reporting Items for Systematic Reviews and 97 Meta-Analyses (PRISMA) (Moher et al., 2009) and performed a meta-analysis as described 98 99 (Antos et al., 2021) with updates described in PRISMA 2020 (Page et al., 2021). We performed a 100 literature search to collect all publications on ACE I/D polymorphisms in centenarians published before May 25, 2022. A total of 80 studies were obtained from the Human Genomic Aging 101 Resource's Longevity Map database, Scopus, PubMed, and Google Scholar using the keywords 102 103 "ACE" OR "angiotensin-converting enzyme" AND "longevity" OR "centenarian" OR "nonagenarian" (subjects 90+ years). Studies of all languages were included. The titles and 104 105 abstracts of each article were imported to Colandr (Cheng et al., 2018) which uses AI and machine-learning algorithms to determine an article's relevance based on text-based evidence. 106 Of the 80 studies initially identified, 37 were excluded as duplicates. The remaining 43 articles 107 108 were then screened in Colandr according to specified inclusion criteria.

109

110 Inclusion criteria

111

112 Studies were included if they met all of the following conditions: (1) evaluation of the ACE I/D polymorphisms and longevity; (2) case-control study design; (3) study provides sample size, 113 genotype data, odds ratio (OR) and 95% confidence interval (CI), or the data necessary to 114 115 calculate the results. The exclusion criteria of the studies were as follows: (1) not relevant to 116 ACE I/D polymorphisms or longevity; (2) review or meta-analysis; (3) minimum long-lived population age < 85 years or unspecified; (4) no control group or maximum control group age >117 118 85 years. Data was then separated into centenarian-only and long-lived (85+ years old) sections. Studies were included in the centenarian-only section if the mean population age was 119 120 > 100. In total, we obtained 13 papers that met all our inclusion criteria for centenarians and 19 121 papers for the long-lived group.

- 122
- 123 Data extraction
- 124

Data were extracted independently by the author and an assistant, and any discrepancies were
 settled by consensus. The data extracted included the author's name, year of publication,

127 ethnicity of the study population, sample size, and genotype numbers in long-lived and control

128 groups. Allele frequencies were calculated if not directly reported. If the study had multiple

- 129 control groups of varying age ranges, the control group was defined as all individuals  $\leq$  85 years
- 130 of age, and data was extracted accordingly.
- 131

132 Data synthesis and assessment of the risk of bias

It is made available under a CC-BY 4.0 International license .


### 133

134 To determine the association between ACE genotype and longevity, the odds ratio (OR) with

- the corresponding 95% confidence interval (CI) was calculated for each genotype (DD, ID, and
- 136 II). All statistical analyses were performed using The Cochrane Collaboration's Review Manager
- 137 (RevMan) Version 5.4 using the random effects statistical model and inverse variance methods.
- 138 The risk of bias in the studies was performed as described by Antos et al., 2021. The result was
- 139 visualized with Risk-of-bias VISualization (robvis) ROBINS-1 (Sterne et al., 2016; McGuinness et
- al., 2021). Bias due to deviations from intended interventions did not apply to this meta-
- 141 analysis, as participants were categorized by age and could not be blinded in which group they

142 were assigned.

143





146 **Figure 1.** Flow diagram of the literature search. A total of 80 studies were gathered from

147 SCOPUS (n = 39), PubMed (n = 26) and Google Scholar (n = 15). Excluding 33 duplicates and 4

It is made available under a CC-BY 4.0 International license .

148 studies with irrelevant titles, 43 remaining studies were selected for abstract examination.

149 Following the abstract screening, 2 studies were excluded for having the wrong study design

and 13 studies were excluded for defining their minimum long-lived population age to be < 85

- 151 years of age. The full-text review was performed on the remaining 28 studies, and 9 of those
- were excluded as the data was not usable, meaning that the study collected and presented data
- in a form other than the frequency of individuals genotypes and that the frequency of
- 154 genotypes was not able to be calculated from the data available.
- 155
- 156 157

## 158 Results

- 159 I. Centenarian results:
- 160

Our literature search is summarized in Figure 1. The extracted data of centenarians from the 161 162 identified studies are summarized in Table 1. The meta-analysis included 13 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da Silva et al., 2018; Faure-Delanef et 163 164 al., 1998; Fiuza-Luces et al., 2011; Nacmias et al., 2007; Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Zhang et al., 2010), involving a total of 2,054 165 centenarians and 10,986 controls. Ethnicities of the studied populations were Caucasian (n = 166 10), Korean (n = 1), Uyghur (n = 1) and Han Chinese (n = 1). This meta-analysis investigated 167 what age groups could be analyzed. We found three age groups that consistently showed up 168 among the previous studies, resulting in centenarians (100+ years old), long-lived groups (85+ 169 years old), and control groups. The range of the control groups was diverse among previous 170 studies. We set the ages of control groups as 18-85 year old which was judged to be inclusive to 171 most of the studies. 172

173

174 The major differences from the previous meta-analysis were as follows. Firstly, we used

different age groups for a more precise understanding of the effect of ACE on longevity. The

176 previous meta-analysis compared the frequencies of various combinations of I and D (i.e., DD

vs. II; DD vs. ID; ID vs. II; DD + ID vs. II; and DD vs. ID + II) (Garatachea et al., 2013), which lacked

178 comparisons among different age groups. Secondly, we excluded a study (Paolisso et al., 2001),

which was used in the previous meta-analysis (Garatachea et al., 2013) for the following reason:
The excluded study used 62-88 years old, which overlapped with the age range for the long-

The excluded study used 62-88 years old, which overlapped with the age range for the longlived group (85+ years old) commonly used in previous studies (see II. Long-Lived Results).

- Finally, we incorporated AI-assisted software to reduce the burden of the meta-analysis studies.
- 183 184

**Table 1**. Characteristics of studies on ACE I/D polymorphisms in centenarians. A total of 13
 studies were included that looked at the frequency of different ACE I/D polymorphisms in
 centenarians.

It is made available under a CC-BY 4.0 International license .

	Year	Ce	ntenarian	(	Control	Ethnicity
		# of subject s	Age (years) Mean ± SD	# of subject s	Age (years) Range	
Schachter et al.	1994	310	100.71 ± 0.13	164	20-70	Caucasian
Faure-Delanef et al.	1998	150	100.6	74	20-70	Caucasian
Bladbjerg et al.	1999	185	>100	199	20-64	Caucasian
Blanche et al.	2001	560	103.1	560	18-70	Caucasian
Panza et al.	2002	63	100.3 ± 1.9	204	19-80	Caucasian
Choi et al.	2003	102	102.4 ± 2.6	7229	20-85	Korean
Panza et al.	2003	82	100 ± 2	252	19-70	Caucasian
Wufuer et al.	2004	42	103.0 ± 3.0	53	65-70	Uyghur
Seripa et al.	2006	64	100.28 ± 1.86	1191	22-59	Caucasian
Nacmias et al.	2007	111	102.4 ± 2.6	192	84 ± 18.2	Caucasian
Zhang et al.	2010	27	>100	79	60-70	Han Chinese
Fiuza-Luces et al.	2011	65	101.7 ± 1.8	283	21.2 ± 2.0	Caucasian
Pereira da Silva et al.	2018	253	100.26 ± 1.98	268	67.51 ± 3.25	Caucasian

189

190

As shown in Figure 2, the association between the DD genotype and exceptional longevity was
analyzed in 13 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da
Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Nacmias et al., 2007;
Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Zhang
et al., 2010). The DD genotype was more frequent among centenarians than in controls, with an
OR of 1.41 (95% Cl: 1.19-1.67, P < 0.0001) with mild heterogeneity (32%), indicating a significant</li>
positive association between the DD genotype and longevity.

It is made available under a CC-BY 4.0 International license .

	Centenarians	w/DD	Control Group	w/DD		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
Schachter 1994	134	310	42	164	9.7%	2.21 [1.46, 3.35]	1994	
Faure-Delanef 1998	47	150	20	74	5.5%	1.23 [0.66, 2.29]	1998	_ <b>-</b>
Bladbjerg 1999	49	185	51	199	8.6%	1.05 [0.66, 1.65]	1999	_ <b>-</b>
Blanche 2001	196	560	171	560	16.2%	1.22 [0.95, 1.57]	2001	+ <b>-</b> -
Panza 2002	30	63	69	204	6.2%	1.78 [1.00, 3.16]	2002	
Choi 2003	15	102	1041	7232	6.6%	1.03 [0.59, 1.78]	2003	_ <b>-</b>
Panza 2003	38	82	100	252	7.6%	1.31 [0.79, 2.17]	2003	- <b></b>
Wufuer 2004	12	42	13	123	3.0%	3.38 [1.40, 8.18]	2004	
Seripa 2006	30	64	510	1191	7.5%	1.18 [0.71, 1.95]	2006	_ <b>-</b>
Nacmias 2007	57	111	82	192	8.3%	1.42 [0.89, 2.26]	2007	+ <b>-</b>
Zhang 2010	8	27	7	79	1.9%	4.33 [1.39, 13.45]	2010	
Fiuza-Luces 2011	31	64	175	434	7.1%	1.39 [0.82, 2.35]	2011	+
Pereira da Silva 2019	104	253	91	268	11.7%	1.36 [0.95, 1.94]	2018	
Total (95% CI)		2013		10972	100.0%	1.42 [1.20, 1.67]		◆
Total events	751		2372					
Heterogeneity: Tau <sup>2</sup> = 0		3. df = 12	$(P = 0.13);  ^2 =$	32%			-	
Test for overall effect: Z			· · · · · · · · · · · · · · · · · · ·				0.	05 0.2 1 5 20
								Favors control Favors centenarians

200

Figure 2: Comparison of DD genotype frequency in centenarians and control groups. The ages of centenarians and control groups are as described in Table 1.

- 203
- 204

As shown in Figure 3, the association between the ID genotype and exceptional longevity was analyzed in 13 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Nacmias et al., 2007; Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Zhang et al., 2010). The ID genotype was found to have an OR of 0.86 (95% CI: 0.76-0.97, P = 0.01) with no evidence of heterogeneity (0%), indicating a significant negative association between the ID genotype and longevity.


- 212
- 213

Study or Subgroup Schachter 1994 Faure-Delanef 1998 Bladbjerg 1999 Blanche 2001 Panza 2002 Choi 2003	Events 148 82 95 261 27 52	Total 310 150 185 560 63	Events 91 38 102 288 400	Total 164 74 199 560	Weight 9.8% 4.5% 8.8% 25.6%	V, Random, 95% Cl 0.73 [0.50, 1.07] 1.14 [0.65, 2.00] 1.00 [0.67, 1.50]	Year 1994 1998 1999	IV, Random, 95% Cl
Faure-Delanef 1998 Bladbjerg 1999 Blanche 2001 Panza 2002	82 95 261 27	150 185 560	38 102 288	74 199	4.5% 8.8%	1.14 [0.65, 2.00]	1998	
Bladbjerg 1999 Blanche 2001 Panza 2002	95 261 27	185 560	102 288	199	8.8%			
Blanche 2001 Panza 2002	261 27	560	288			1.00 [0.67, 1.50]	1999	
Panza 2002	27			560	25.600			
		63	400		20.0%	0.82 [0.65, 1.04]	2001	
Choi 2003	52		109	204	4.3%	0.65 [0.37, 1.16]	2002	
		102	3549	7232	9.2%	1.08 [0.73, 1.60]	2003	
Panza 2003	34	82	118	252	5.5%	0.80 [0.49, 1.33]	2003	
Wufuer 2004	13	42	56	123	2.5%	0.54 [0.25, 1.13]	2004	
Seripa 2006	28	64	526	1191	5.5%	0.98 [0.59, 1.63]	2006	
Nacmias 2007	40	111	84	192	6.1%	0.72 [0.45, 1.17]	2007	
Zhang 2010	9	27	26	79	1.6%	1.02 [0.40, 2.58]	2010	
Fiuza-Luces 2011	21	64	191	434	4.6%	0.62 [0.36, 1.08]	2011	
Pereira da Silva 2019	111	253	119	268	11.8%	0.98 [0.69, 1.38]	2019	
Total (95% CI)		2013		10972	100.0%	0.85 [0.76, 0.96]		•
Total events	921		5297					
Heterogeneity: Tau <sup>2</sup> = 0.00	0; Chi <sup>2</sup> = 8.90	), df = 12		0%			+	
Test for overall effect: Z = 2	•						0.2	0.5 1 2 5 Favors control Favors centenarians

- Figure 3: Comparison of ID genotype frequency in centenarians and control groups. The ages of
- 216 centenarians and control groups are described in Table 1.
- 217
- 218
- As shown in Figure 4, the association between the II genotype and exceptional longevity was
- analyzed in 13 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da
- Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Nacmias et al., 2007;

It is made available under a CC-BY 4.0 International license .

- 222 Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Zhang
- et al., 2010). The II genotype was found to have an OR of 0.81 (95% CI: 0.66-0.98, P = 0.03) with
- mild heterogeneity (28%), indicating a significant negative association between the II genotype
- and longevity.
- 226
- 227



230 centenarians and control groups are as described in Table 1.

231

228

229

232

233 II. Long-Lived Results:

234

Table 2 summarizes the data of long-lived groups. The meta-analysis included 19 studies, with 13 centenarian-only studies, and 5 studies that included both nonagenarians and centenarians (Arkhipova et al., 2014; Kolovou et al., 2014; Lo Sasso et al., 2012; Oscanoa et al., 2020; Yang et al., 2009), and 1 study with individuals 85 years and older (Heijmans et al., 1999), involving a total of 3,421 long-lived individuals (85+ years old) and 11,959 controls. Ethnicities of the studied populations were Caucasian (n = 13), Korean (n = 1), Uyghur (n = 1), Han Chinese (n = 2), Russian/Yakut (n = 1), and Peruvian (n = 1).

242

The association between the DD genotype and exceptional longevity was analyzed in 18 studies
(Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da Silva et al., 2018;
Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Kolovou et al., 2014; Lo Sasso et al., 2012;

246 Nacmias et al., 2007; Oscanoa et al., 2020; Panza et al., 2002, 2003; Schachter et al., 1994;

247 Seripa et al., 2006; Wufuer et al., 2004; Yang et al., 2009; Zhang et al., 2010). The DD genotype

was found to have an OR of 1.32 (95% CI: 1.19-1.47, P < 0.00001) with mild heterogeneity

249 (30%), indicating a significant positive association between the DD genotype and longevity.

250

251

Table 2. Characteristics of studies on ACE I/D polymorphisms in long-lived individuals (85+ years
 old).

It is made available under a CC-BY 4.0 International license .

	Year	Lo	ong-lived		Control	Ethnicity
		# of subject s	Age (years) Mean ± SD	# of subject s	Age (years) Range/Mean ± SD	
Schachter et al.	1994	310	100.71 ± 0.13	164	20-70	Caucasian
Faure-Delanef et al.	1998	150	100.6	74	20-70	Caucasian
Bladbjerg et al.	1999	185	>100	199	20-64	Caucasian
Heijmans et al.	1999	353	85-100	250	18-40	Caucasian
Blanche et al.	2001	560	103.1	560	18-70	Caucasian
Panza et al.	2002	63	100.3 ± 1.9	204	19-80	Caucasian
Choi et al.	2003	102	102.4 ± 2.6	7229	20-85	Korean
Panza et al.	2003	82	100 ± 2	252	19-70	Caucasian
Wufuer et al.	2004	42	103.0 ± 3.0	53	65-70	Uyghur
Seripa et al.	2006	64	100.28 ± 1.86	1191	22-59	Caucasian
Nacmias et al.	2007	111	102.4 ± 2.6	192	84 ± 18.2	Caucasian
Yang et al.	2009	399	>90	302	<60	Han Chinese
Zhang et al.	2010	27	>100	79	60-70	Han Chinese
Fiuza-Luces et al.	2011	65	101.7 ± 1.8	283	21.2 ± 2.0	Caucasian
Lo Sasso et al.	2012	361	97	394	39	Caucasian
Arkhipova et al.	2014	44	>90	115	60-74	Russian, Yakut
Kolovou et al.	2014	198	≥90	105	18-79	Caucasian
Pereira da Silva et al.	2018	253	100.26 ± 1.98	268	67.51 ± 3.25	Caucasian
Oscanoa et al.	2020	6	>85	14	<65	Peruvian

It is made available under a CC-BY 4.0 International license .




Figure 5. Comparison of DD genotype frequency in long-lived and control groups. The ages of
 long-lived and control groups are described in Table 1

long-lived and control groups are described in Table 1.

259

260

As shown in Figure 6, the association between the ID genotype and exceptional longevity was

analyzed in 18 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da

Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Kolovou et al., 2014; Lo

264 Sasso et al., 2012; Nacmias et al., 2007; Oscanoa et al., 2020; Panza et al., 2002, 2003;

Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Yang et al., 2009; Zhang et al.,

266 2010).

267

The ID genotype was found to have an OR of 0.92 (95% CI: 0.84-1.02, P = 0.11) with no evidence

of heterogeneity (0%). There was no significant difference in the frequency of the ID genotype
 between the long-lived (85+ years old) and control groups.

271

It is made available under a CC-BY 4.0 International license .

	Long-Lived		Control			Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% Cl
Schachter 1994	148	310	91	164	6.1%	0.73 [0.50, 1.07]	1994	
Faure-Delanef 1998	82	150	38	74	2.9%	1.14 [0.65, 2.00]	1998	
Bladbjerg 1999	95	185	102	199	5.5%	1.00 [0.67, 1.50]	1999	-
Heijmans 1999	177	353	122	250	8.4%	1.06 [0.76, 1.46]	1999	+
Blanche 2001	261	560	288	560	16.1%	0.82 [0.65, 1.04]	2001	
Panza 2002	27	63	109	204	2.7%	0.65 [0.37, 1.16]	2002	
Panza 2003	34	82	118	252	3.5%	0.80 [0.49, 1.33]	2003	
Choi 2003	52	102	3549	7229	5.8%	1.08 [0.73, 1.59]	2003	+-
Wufuer 2004	59	144	56	123	3.8%	0.83 [0.51, 1.35]	2004	
Seripa 2006	28	64	526	1191	3.5%	0.98 [0.59, 1.63]	2006	_ <b>+</b> _
Nacmias 2007	40	111	84	192	3.8%	0.72 [0.45, 1.17]	2007	
Yang 2009	179	399	130	302	9.8%	1.08 [0.80, 1.46]	2009	+
Zhang 2010	9	27	26	79	1.0%	1.02 [0.40, 2.58]	2010	
Fiuza-Luces 2011	47	111	191	434	5.0%	0.93 [0.61, 1.42]	2011	
Lo Sasso 2012	156	361	172	394	10.7%	0.98 [0.74, 1.31]	2012	+
Kolovou 2014	85	198	46	100	3.8%	0.88 [0.54, 1.43]	2014	
Pereira da Silva 2019	111	253	119	268	7.4%	0.98 [0.69, 1.38]	2019	-
Oscanoa 2020	4	6	3	14	0.2%	7.33 [0.88, 61.33]	2020	
Total (95% CI)		3479		12029	100.0%	0.93 [0.84, 1.02]		•
Total events	1594		5770					
Heterogeneity: Chi <sup>2</sup> = 1:	2.23, df = 17 (	P = 0.79	); I <sup>2</sup> = 0%					
Test for overall effect: Z	= 1.60 (P = 0)	11)						Favors control Favors long-lived

**Figure 6.** Comparison of ID genotype frequency in long-lived and control groups. The ages of

275 long-lived and control groups are described in Table 1.

276

273

277

278 As shown in Figure 7, the association between the II genotype and exceptional longevity was analyzed in 19 studies (Arkhipova et al., 2014; Bladbjerg et al., 1999; Blanche et al., 2001; Choi 279 et al., 2003; Pereira da Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; 280 281 Kolovou et al., 2014; Lo Sasso et al., 2012; Nacmias et al., 2007; Oscanoa et al., 2020; Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Yang et al., 2009; 282 Zhang et al., 2010). Arkhipova et al., 2014 only provided raw frequency data for the II genotype 283 and thus was not included in the DD or ID analyses. The II genotype was found to have an OR of 284 0.80 (95% CI: 0.71-0.90, P = 0.002) with mild heterogeneity (30%), indicating a significant 285 286 negative association between the II genotype and longevity. The risk of bias of the studies was assessed using ROBINS-1 (Method). As shown in Figure 8, the result suggests an overall low risk 287

288 of bias.

289

It is made available under a CC-BY 4.0 International license .

	Long-Live		Contro			Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Fixed, 95% Cl	Year	IV, Fixed, 95% Cl
Schachter 1994	56	310	31	164	5.8%	0.95 [0.58, 1.54]	1994	
Faure-Delanef 1998	21	150	16	74	2.6%	0.59 [0.29, 1.21]	1998	
Bladbjerg 1999	41	185	46	199	6.0%	0.95 [0.59, 1.53]	1999	-+-
Heijmans 1999	73	353	62	250	9.2%	0.79 [0.54, 1.16]	1999	
Blanche 2001	103	560	101	560	14.9%	1.02 [0.76, 1.39]	2001	+
Panza 2002	6	63	26	204	1.6%	0.72 [0.28, 1.84]	2002	
Panza 2003	10	82	34	252	2.4%	0.89 [0.42, 1.89]	2003	
Choi 2003	35	102	2639	7229	8.1%	0.91 [0.60, 1.37]	2003	
Wufuer 2004	45	144	54	123	5.5%	0.58 [0.35, 0.96]	2004	_ <b>_</b>
Seripa 2006	6	64	155	1191	1.9%	0.69 [0.29, 1.63]	2006	
Nacmias 2007	14	111	26	192	2.8%	0.92 [0.46, 1.85]	2007	
Yang 2009	168	399	129	302	15.0%	0.98 [0.72, 1.32]	2009	-
Zhang 2010	10	27	46	79	1.7%	0.42 [0.17, 1.04]	2010	
Fiuza-Luces 2011	15	111	68	434	3.8%	0.84 [0.46, 1.54]	2011	
Lo Sasso 2012	44	361	90	394	8.9%	0.47 [0.32, 0.69]	2012	
Arkhipova 2014	14	44	47	115	2.5%	0.68 [0.32, 1.41]	2014	
Kolovou 2014	35	198	18	100	3.5%	0.98 [0.52, 1.83]	2014	<b>_</b>
Pereira da Silva 2019	15	253	44	268	3.6%	0.32 [0.17, 0.59]	2019	
Oscanoa 2020	2	6	9	14	0.3%	0.28 [0.04, 2.09]	2020	
Total (95% CI)		3523		12144	100.0%	0.79 [0.70, 0.88]		•
Total events	713		3641					
Heterogeneity: Chi <sup>2</sup> = 2	7.28, df = 18	(P = 0.0	)7); l² = 34	4%				
Test for overall effect: Z	= 4.04 (P <	0.0001)						0.01 0.1 1 10 10 Favors control Favors long-lived

292 **Figure 7.** Comparison of II genotype frequency in long-lived and control groups. The ages of

long-lived and control groups are described in Table 1.

294

291

It is made available under a CC-BY 4.0 International license .

				Ri	sk of bia	s domai	ns		
		D1	D2	D3	D4	D5	D6	D7	Overall
	Schachter et al., 1994	+	+	+	?	+	+	+	+
	Faure-Delanef et al., 1998	+	+	+	?	+	+	+	+
	Bladbjerg et al., 1999	+	+	+	?	+	+	+	+
	Heijmans et al., 1999	+	+	+	?	+	+	+	+
	Blanche et al., 2001	+	+	+	?	+	+	+	+
	Panza et al., 2002	+	+	+	?	+	+	+	+
	Choi et al., 2003	+	+	+	?	+	+	+	+
	Panza et al., 2003	+	+	+	?	+	+	+	+
	Wufuer et al., 2004	+	+	+	?	+	+	+	+
Study	Seripa et al., 2006	+	+	+	?	+	+	+	+
	Nacmias et al., 2007	+	+	+	?	+	+	+	+
	Yang et al., 2009	+	+	+	?	+	+	+	+
	Zhang et al., 2010	+	+	+	?	+	+	+	+
	Fiuza-Luces et al., 2011	+	+	+	?	+	+	+	+
	Lo Sasso et al., 2012	+	+	+	?	+	+	+	+
	Arkhipova et al., 2014	+	+	+	?	-	+	+	+
	Kolovou et al., 2014	+	+	?	?	+	+	+	+
	Da Silva et al., 2018	+	+	+	?	+	+	+	+
	Oscanoa et al., 2020	+	-	+	?	+	+	+	+
		D2: Bias D3: Bias	due to co due to se in classifie	lection of p cation of ir	participant nterventior	IS.	ations	Judgem - Mo + Lo	oderate

Risk of bias domains

296

297

Figure 8A. Traffic light plot showing the assessment of the risk of bias using ROBINS-1.

D5: Bias due to missing data.


D6: Bias in measurement of outcomes. D7: Bias in selection of the reported result.

D4: Bias due to deviations from intended interventions.

No information

It is made available under a CC-BY 4.0 International license .





**Figure 8B**. Summary plot showing the assessment of the risk of bias using ROBINS-1.

301 302

299

303 **Discussion**:

304

305 Centenarians are the fastest-growing demographic group of the world's population, having roughly doubled every decade since 1950 (Wilcox et al., 2011). It has been nearly a decade 306 since the most recent meta-analysis has been published in 2013 (Garatachea et al., 2013) and 307 additional studies on centenarians and nonagenarians have been conducted that further 308 309 elucidate the association between ACE genotype and longevity. In addition, the use of AI and machine-learning software has aided in the search and screening process to compile even more 310 311 studies and process the associated data. Our meta-analysis suggests, with increased confidence, that there is a significant positive association of the DD genotype with exceptional 312 longevity, across populations of different ethnicities. It has been reported that serum ACE levels 313 correlate in the order of DD > ID > II in which DD is the highest (Rigat et al., 1990; Tiret et al., 314 315 1992; Tomita et al., 1996). The higher levels of ACE were correlated with increased lifespans, 316 especially more in centenarians than in long-lived controls.

317

318 The results present a couple of paradoxes in which the D-allele has been reported as a risk factor for hypertension (Li et al., 2011), CVD (Zintzaras et al., 2008), pneumonia (Nie et al., 319 320 2014) and COVID-19 (Yamamoto et al., 2020), all of which are major causes of death in older 321 people. However, the DD genotype has been associated with a decreased risk of Alzheimer's 322 disease, potentially due to ACE's ability to inhibit amyloid beta aggregation and degrade A beta-(1-40) (Hu et al., 2001; Kölsch et al., 2005; Lehmann et al., 2005). Although the protective effect 323 324 of the D-allele against Alzheimer's disease does not fully explain the higher proportion of DD individuals in centenarian cohorts, the D-allele or DD genotype may impart a health risk while 325 326 also providing a long-term longevity advantage. The middle-life crisis theory of aging (Murakami 327 et al., 2011; Murakami, 2013; Machino et al., 2014; Le et al., 2021), in which midlife events are the catalyst for the transition from normal aging to a more advanced pathological state, can be 328 used to explain ACE's dual functions as an angiotensin-converting enzyme and an amyloid-329 330 degrading enzyme (Le et al., 2021); low levels of ACE plasma activity, associated with the II genotype, may initially confer stress resistance before midlife, but will be insufficient to counter 331 332 the abnormal accumulation of beta-amyloid when it begins and thus lead to higher mortality

It is made available under a CC-BY 4.0 International license .

rates earlier in the aging process due to AD, while DD individuals who had survived midlife

- comorbidities would now have lower mortality rates from AD. However, this does not fully
- explain the ACE paradox, as Alzheimer's disease is only one of many diseases that affect older
- people. As the full role of ACE in the human body has not been determined, the D-allele may
- 337 have some neuroendocrine or immunomodulatory functions that have yet to be discovered
- 338 (Costerousse et al., 1993) that may further explain ACE's role in longevity. It raises an
- 339 unanswered key question how exceptional longevity is associated with positive risks of age-
- onset diseases that may increase the risk of mortality.
- 341

Another paradox is that inhibition of ACE by mutations or drugs can extend lifespans in model systems from nematodes, fruit flies, and mammals (reviewed in Le et al., 2021; Egan et al.,

- 2022). The observation raises awareness that life-extension interventions in model systems
- may be different from exceptional longevity in humans. Thus, it raises another unanswered key
- 346 guestion of whether or not exceptional longevity in humans shares common underlying
- 347 mechanisms with life extension in model systems.
- 348

349 Our meta-analysis includes a comprehensive review of studies done on centenarians, from

350 Schachter's initial study in 1994 up to the present, for a total of 2,054 centenarians. We did not

- 351 limit the literature search to only studies written in English, thus our data represents all of the
- 352 current ACE centenarian studies in the databases searched. The results corroborated the
- 353 positive association between the DD genotype and exceptional longevity and the negative
- association between the II genotype and exceptional longevity that had been noted in previous
- 355 meta-analyses. A novel finding was that the ID genotype, which had previously shown no
- 356 significant associations with longevity, was found to have a significant negative association with
- 357 longevity in the centenarian-only analysis.
- 358

359 It is implicated that the effect of ACE on health may differ among different age groups (Duc et 360 al., 2021). Thus, we compared the centenarian-only data with the long-lived (85+ years old) data. We found that the distribution of ACE DD and II genotypes were consistent across both 361 362 age groups, with strong associations in the DD genotype with exceptional longevity and with negative associations in the II genotype. Interestingly, the ID genotype had a significant 363 negative association among centenarians but did not show a significant association among 364 365 long-lived groups. The straightforward interpretations are as follows: (1) The DD genotype is associated with centenarians and is long-lived, while the D alleles follow the inheritance pattern 366 of autosomal recessive; (2) The II genotype is negatively associated with longevity in both age 367 368 groups; (3) The ID genotype shows a weakly negative association with centenarians, while the 369 trend was not significant in long-lived control. Thus, more detailed studies with a series of ages 370 will be needed.

371

372 The limitations of this study are as follows. Firstly, it can be summarized as a general limitation

of the meta-analysis method. Each search engine list the papers which are indexed by its

- 374 criteria, which may miss relevant studies. We included three search engines to reduce this risk
- of missing studies. Secondly, related to the first limitation is that the criteria to analyze the data
- 376 rely on the criteria used in each study. For example, control groups of the past studies ranged

It is made available under a CC-BY 4.0 International license .

broadly and diverse (18-85 years old). There was a lack of detailed age groups to compare the 377 378 effect of ACE. Thus, we were not able to have a series of ages to define age-dependent 379 enrichment of the ACE D and I alleles. Thirdly, another limitation is that the vast majority of the centenarian studies on ACE used Caucasian populations. Selectively analyzing the studies of 380 381 Caucasian populations gives the same results as the pooled data, indicating that there were no 382 major differences in association across ethnicity within this present review. However, there 383 were not enough Asian studies to sufficiently analyze the strength of association within Asian populations only. We also did not find any studies on ACE polymorphisms in Hispanic/Latino or 384 Black centenarian cohorts in our literature search. For future meta-analyses, a greater diversity 385 386 of such studies should be taken to better illuminate the role of ACE in aging populations across all different environmental or lifestyle risk factors. 387

388

# 389390 Conclusions:

391

392 Our meta-analysis suggests a significant positive association between the ACE DD genotype 393 with centenarians and long-lived groups. Although ACE polymorphisms are a risk factor for Alzheimer's disease and age-onset diseases that may contribute to mortality, the ACE DD 394 genotype but not the ID genotype was in favor of exceptional longevity over the mortality 395 expected in older people. The DD genotype is associated with a reduced risk of Alzheimer's 396 397 disease and increased longevity. It is consistent with an ACE function as an amyloid degradation enzyme, which may be important in exceptional longevity in humans. Additionally, 398 the DD genotype causes a high circulating ACE. In contrast, the DD genotype is also associated 399 400 with an increased risk of various other diseases. They include hypertension (Li et al., 2011), ischemic stroke (Zhang et al., 2012), coronary artery disease (Zintzaras et al., 2008), left 401 402 ventricular hypertrophy (Li et al., 2012) and pneumonia (Nie et al., 2014). Some of these 403 diseases, including hypertension and cardiovascular conditions (stroke and coronary artery 404 disease), are associated with the risks of COVID-19 mortality (Antos et al., 2021). The DD genotype is associated with higher COVID-19 mortality (Yamamoto et al., 2020). It may imply 405 406 disease interactions mediated by the D allele. The underlying mechanisms of human longevity remain unclear, especially when considering the D-allele's role as a risk factor for many age-407 408 related comorbidities. Further studies on nonagenarians and centenarians of different 409 backgrounds may provide better insight into the role of ACE as a longevity gene. 410 411 412 Author Contributions: L.L. was involved in data collection, organization of AI components, data 413 analysis and writing of the manuscript. S.M. directed and guided all the research process. 414 415 Funding: This research received no external funding. 416 417 Institutional Review Board Statement: Not applicable. 418 419 Informed Consent Statement: Not applicable.

It is made available under a CC-BY 4.0 International license .

- **Data Availability Statement:** The data supporting the reported results have been made
- 422 available within the manuscript.
- **Conflicts of Interest:** The authors declare no conflicts of interest.

## 427 References

- Antos A, Kwong ML, Balmorez T, Villanueva A, Murakami S. (2021) Unusually High Risks of COVID-19 Mortality with Age-Related Comorbidities: An Adjusted Meta-Analysis Method to Improve the Risk Assessment of Mortality Using the Comorbid Mortality Data. Infect Dis Rep. 13(3):700-711. doi: 10.3390/idr13030065. PMID: 34449622;
   PMCID: PMC8395741.
- Arkhipova, N., Popova, E. and Grigorieva, L. (2014) The angiotension converting enzyme
  (ACE) gene I/D polymorphism in different ethnic groups of geriatric age living in the Far
  North. Health, 6, 426-431. doi: 10.4236/health.2014.65060.
- 436
   3. Batrinos ML. (2008) The length of life and eugeria in classical Greece. Hormones

   437
   (Athens). 7(1):82-3. doi: 10.14310/horm.2002.1111041. PMID: 18359748.
- Beohar N, Damaraju S, Prather A, Yu QT, Raizner A, Kleiman NS, Roberts R, Marian AJ.
   (1995) Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery
   disease. J Investig Med. 43(3):275-80. PMID: 7614074.
- 441 5. Bladbjerg EM, Andersen-Ranberg K, de Maat MP, Kristensen SR, Jeune B, Gram J,
  442 Jespersen J. (1999) Longevity is independent of common variations in genes associated
  443 with cardiovascular risk. Thromb Haemost. 82(3):1100-5. PMID: 10494771.
- Blanché H, Cabanne L, Sahbatou M, Thomas G. (2001) A study of French centenarians:
  are ACE and APOE associated with longevity? C R Acad Sci III. 324(2):129-35. doi:
  10.1016/s0764-4469(00)01274-9. PMID: 11280044.
- Cheng, SH., Augustin, C., Bethel, A., Gill, D., Anzaroot, S., Brun, J., DeWilde, B., Minnich,
  R., Garside, R., Masuda, Y., Miller, DC., Wilkie, D., Wongbusarakum, S. and McKinnon,
  MC. (2018) Using machine learning to advance synthesis and use of conservation and
  environmental evidence. Conservation Biology, 32: 762-764. doi:10.1111/cobi.1311
- 8. Choi YH, Kim JH, Kim DK, Kim JW, Kim DK, Lee MS, Kim CH, Park SC. (2003) Distributions
   of ACE and APOE polymorphisms and their relations with dementia status in Korean
   centenarians. J Gerontol A Biol Sci Med Sci. 58(3):227-31. doi:
- 454 10.1093/gerona/58.3.m227. PMID: 12634288.
- Costa D, Scognamiglio M, Fiorito C, Benincasa G, Napoli C. Genetic background,
   epigenetic factors and dietary interventions which influence human longevity.
   Biogerontology. 2019 Oct;20(5):605-626. doi: 10.1007/s10522-019-09824-3. Epub 2019
   Jul 15. PMID: 31309340.
- 459 10. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. (1993) Angiotensin I-converting
  460 enzyme in human circulating mononuclear cells: genetic polymorphism of expression in
  461 T-lymphocytes. Biochem J. 290 (Pt1)(Pt1):33-40. doi: 10.1042/bj2900033. PMID:
  462 8382480; PMCID: PMC1132379.
- 463 11. Faure-Delanef L, Baudin B, Bénéteau-Burnat B, Beaudoin JC, Giboudeau J, Cohen D.
  464 (1998) Plasma concentration, kinetic constants, and gene polymorphism of angiotensin
  465 I-converting enzyme in centenarians. Clin Chem. 44(10):2083-7. PMID: 9761238.
- Fiuza-Luces C, Ruiz JR, Rodríguez-Romo G, Santiago C, Gómez-Gallego F, Cano-Nieto A,
  Garatachea N, Rodríguez-Moreno I, Morán M, Lucia A. (2011) Is the ACE I/D
  polymorphism associated with extreme longevity? A study on a Spanish cohort. J Renin
  Angiotensin Aldosterone Syst. 12(3):202-7. doi: 10.1177/1470320310391505. Epub 2011
- 470 Feb 17. PMID: 21330423.

471	13.	Garatachea N, Marín PJ, Lucia A. (2013) The ACE DD genotype and D-allele are
472		associated with exceptional longevity: a meta-analysis. Ageing Res Rev. 12(4):1079-87.
473		doi: 10.1016/j.arr.2013.04.001. Epub 2013 Apr 23. PMID: 23623925.
474	14.	Gareri P, Lacava R, Rossi MG, Iorio C, Galasso MA, Pansini L, Curti A, Mercurio M, Olivo
475		D, Mattace R. (1996) Hypertension in a group of centenarians. Arch Gerontol Geriatr. 22
476		Suppl 1:373-6. doi: 10.1016/0167-4943(96)86964-0. PMID: 18653059.
477	15.	Heijmans BT, Westendorp RG, Knook DL, Kluft C, Slagboom PE. (1999) Angiotensin I-
478		converting enzyme and plasminogen activator inhibitor-1 gene variants: risk of mortality
479		and fatal cardiovascular disease in an elderly population-based cohort. J Am Coll Cardiol.
480		34(4):1176-83. doi: 10.1016/s0735-1097(99)00337-x. PMID: 10520809.
481	16.	Hu J, Igarashi A, Kamata M, Nakagawa H. (2001) Angiotensin-converting enzyme
482		degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation,
483		deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem. 276(51):47863-8. doi:
484		10.1074/jbc.M104068200. Epub 2001 Oct 16. PMID: 11604391.
485	17.	Jopp DS, Boerner K, Rott C. (2016) Health and Disease at Age 100. Dtsch Arztebl Int.
486		113(12):203-10. doi: 10.3238/arztebl.2016.0203. Erratum in: Dtsch Arztebl Int. 2016
487		113(22-23):395. PMID: 27118718; PMCID: PMC5400033.
488	18.	Kolovou G, Kolovou V, Vasiliadis I, Giannakopoulou V, Mihas C, Bilianou H, Kollia A,
489		Papadopoulou E, Marvaki A, Goumas G, Kalogeropoulos P, Limperi S, Katsiki N,
490		Mavrogeni S. (2013) The frequency of 4 common gene polymorphisms in
491		nonagenarians, centenarians, and average life span individuals. Angiology. 65(3):210-5.
492		doi: 10.1177/0003319712475075. PMID: 23389097.
493	19.	Kölsch H, Jessen F, Freymann N, Kreis M, Hentschel F, Maier W, Heun R. (2005) ACE I/D
494		polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia.
495		Neurosci Lett. 377(1):37-9. doi: 10.1016/j.neulet.2004.11.062. Epub 2004 Dec 10. PMID:
496		15722183.
497	20.	Le D, Brown L, Malik K, Murakami S. (2021) Two Opposing Functions of Angiotensin-
498		Converting Enzyme (ACE) That Links Hypertension, Dementia, and Aging. Int J Mol Sci.
499		22(24):13178. doi: 10.3390/ijms222413178. PMID: 34947975; PMCID: PMC8707689.
500	21.	Le D, Crouch N, Villanueva A, Ta P, Dmitriyev R, Tsunzi M and Murakami S. (2020)
501		Evidence-Based Genetics and Identification of Key Human Alzheimer's Disease Alleles
502		with Co-morbidities. J Neurol Exp Neurosci 6(1): 20-24.
503	22.	Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, van Duijn
504		CM, Kehoe PG. (2005) Large meta-analysis establishes the ACE insertion-deletion
505		polymorphism as a marker of Alzheimer's disease. Am J Epidemiol. 162(4):305-17. doi:
506		10.1093/aje/kwi202. Epub 2005 Jul 20. PMID: 16033878.
507	23.	Li X, Li Y, Jia N, Guo S, Chu S, Niu W. (2012) Angiotensin-converting enzyme gene
508		deletion allele increases the risk of left ventricular hypertrophy: evidence from a meta-
509		analysis. Mol Biol Rep. 39(12):10063-75. doi: 10.1007/s11033-012-1875-6. Epub 2012 Jul
510		7. PMID: 22773337.
511	24.	Li Y. (2012) Angiotensin-converting enzyme gene insertion/deletion polymorphism and
512		essential hypertension in the Chinese population: a meta-analysis including 21,058
513		participants. Intern Med J. 2012 Apr;42(4):439-44. doi: 10.1111/j.1445-
514		5994.2011.02584.x. PMID: 21883781.

515	25. Lo Sasso, B., Bellia, C., Tomaiuolo, R., Zarrilli, F., Scorza, M., Caruso, A., et al. (2013).
516	Polimorfismo I/D del gene per l'enzima di conversione dell'angiotensina (ACE): gene
517	della longevità o fattore di rischio nella patologia ipertensiva?. Biochimica Clinica,
518	37(37), 461-464.
519	26. Machino K, Link CD, Wang S, Murakami H, Murakami S. A semi-automated motion-
520	tracking analysis of locomotion speed in the C. elegans transgenics overexpressing beta-
521	amyloid in neurons. Front Genet. 2014 Jul 4;5:202. doi: 10.3389/fgene.2014.00202.
522	PMID: 25071831; PMCID: PMC4082091.
523	27. McGuinness LA, Higgins JPT. (2021) Risk-of-bias VISualization (robvis): An R package and
524	Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 12(1):55-61.
525	doi: 10.1002/jrsm.1411. PMID: 32336025.
526	28. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. (2009) Preferred reporting
527	items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.
528	6(7):e1000097. doi: 10.1371/journal.pmed.1000097. PMID: 19621072; PMCID:
529	PMC2707599.
530	29. Montagu JD. (1994) Length of life in the ancient world: a controlled study. J R Soc Med.
531	87(1):25-6. PMID: 8308825; PMCID: PMC1294277.
532	30. Murakami, S. (2013) Age-dependent modulation of learning and memory in C. elegans.
533	In Menzel R and Benjamin P.R. (Eds.) Invertebrate Learning and Memory; Handbook of
534	Behavioral Neuroscience. Elsevier/Academic Press. Ch.12, Pages 140-150.
535	31. Murakami, S., Cabana, K., Anderson, D. (2011) Current advances in the study of
536	oxidative stress and age-related memory impairment in <i>C. elegans</i> . In Farooqui, T.
537	Farooqui, A. (Ed.) Molecular aspects of oxidative stress on cell signaling in vertebrates
538	and invertebrates, John Wiley & Sons, Hoboken, NJ. Ch 25, Pages 347-360.
539	32. Murakami S, Lacayo P. (2022) Biological and disease hallmarks of Alzheimer's disease
540	defined by Alzheimer's disease genes. Front Aging Neurosci. 14:996030. doi:
541	10.3389/fnagi.2022.996030. PMID: 36437990; PMCID: PMC9682170.
542	33. Nacmias B, Bagnoli S, Tedde A, Cellini E, Bessi V, Guarnieri B, Ortensi L, Piacentini S,
543	Bracco L, Sorbi S. (2007) Angiotensin converting enzyme insertion/deletion
544	polymorphism in sporadic and familial Alzheimer's disease and longevity. Arch Gerontol
545	Geriatr. 45(2):201-6. doi: 10.1016/j.archger.2006.10.011. Epub 2006 Dec 19. PMID:
546	17182125.
547	34. Nie W, Zang Y, Chen J, Liu T, Xiao L, Xiu Q. (2014) Angiotensin-converting enzyme I/D
548	polymorphism is associated with pneumonia risk: a meta-analysis. J Renin Angiotensin
549	Aldosterone Syst. 15(4):585-92. doi: 10.1177/1470320313507622. Epub 2014 Feb 4.
550	PMID: 24496515.
551	35. Oscanoa TJ, Cieza EC, Lizaraso-Soto FA, Guevara ML, Fujita RM, Romero-Ortuño R.
552	(2020) Angiotensin-Converting Enzyme (ACE) genetic variation and longevity in Peruvian
553	older people: a cross-sectional study. Ann Hum Biol. 47(3):309-312. doi:
554	10.1080/03014460.2020.1748227. PMID: 32281429.
555	36. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L,
556	Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu
557	MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J,
558	Tricco AC, Welch VA, Whiting P, Moher D. (2021) The PRISMA 2020 statement: an

559	updated guideline for reporting systematic reviews. BMJ. 372:n71. doi:
560	10.1136/bmj.n71. PMID: 33782057; PMCID: PMC8005924.
561	37. Panza, F., Solfrizzi, V., D'Introno, A., Capurso, C., Basile, A.M., Colacicco, A.M., Sabba, M.,
562	Noya, R., Capurso, A. (2002) Apolipoprotein and angiotensin converting enzyme genes:
563	regional differences and extreme longevity in Europe. Archives of Gerontology and
564	Geriatrics Supplement 8, 247–251
565	38. Panza F, Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Kehoe PG, Capurso A. (2003)
566	Angiotensin I converting enzyme (ACE) gene polymorphism in centenarians: different
567	allele frequencies between the North and South of Europe. Exp Gerontol. 38(9):1015-20.
568	doi: 10.1016/s0531-5565(03)00154-2. PMID: 12954489.
569	39. Pereira da Silva A, Matos A, Aguiar L, Ramos-Marques N, Ribeiro R, Gil Â, Gorjão-Clara J,
570	Bicho M. (2019) Hypertension and longevity: role of genetic polymorphisms in renin-
571	angiotensin-aldosterone system and endothelial nitric oxide synthase. Mol Cell
572	Biochem. 455(1-2):61-71. doi: 10.1007/s11010-018-3470-1. PMID: 30460536.
573	40. Revelas M, Thalamuthu A, Oldmeadow C, Evans TJ, Armstrong NJ, Kwok JB, Brodaty H,
574	Schofield PR, Scott RJ, Sachdev PS, Attia JR, Mather KA. (2018) Review and meta-analysis
575	of genetic polymorphisms associated with exceptional human longevity. Mech Ageing
576	Dev. 175:24-34. doi: 10.1016/j.mad.2018.06.002. PMID: 29890178.
577	41. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. (1990) An
578	insertion/deletion polymorphism in the angiotensin I-converting enzyme gene
579	accounting for half the variance of serum enzyme levels. J Clin Invest. 86(4):1343-6. doi:
580	10.1172/JCI114844. PMID: 1976655; PMCID: PMC296868.
581	42. Roser M, Ortiz-Ospina E, Ritchie H (2013) Life Expectancy. OurWorldInData.org.
582	Retrieved on Nov 29, 2022 from: https://ourworldindata.org/life-expectancy
583	43. Schächter F, Faure-Delanef L, Guénot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D.
584	(1994) Genetic associations with human longevity at the APOE and ACE loci. Nat Genet.
585	6(1):29-32. doi: 10.1038/ng0194-29. PMID: 8136829.
586	44. Seripa D, Franceschi M, Matera MG, Panza F, Kehoe PG, Gravina C, Orsitto G, Solfrizzi V,
587	Di Minno G, Dallapiccola B, Pilotto A. (2006) Sex differences in the association of
588	apolipoprotein E and angiotensin-converting enzyme gene polymorphisms with healthy
589	aging and longevity: a population-based study from Southern Italy. J Gerontol A Biol Sci
590	Med Sci. 61(9):918-23. doi: 10.1093/gerona/61.9.918. PMID: 16960022.
591	45. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D,
592	Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ,
593	Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein
594	HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L,
595	Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. (2016) ROBINS-
596	I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ.
597	355:i4919. doi: 10.1136/bmj.i4919. PMID: 27733354; PMCID: PMC5062054.
598	46. Tomita H, Ina Y, Sugiura Y, Sato S, Kawaguchi H, Morishita M, Yamamoto M, Ueda R.
599	(1997) Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis.
600	Am J Respir Crit Care Med. 156(1):255-9. doi: 10.1164/ajrccm.156.1.9612011. PMID:
601	9230757.

602	47. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. Evidence, from
603	combined segregation and linkage analysis, that a variant of the angiotensin I-converting
604	enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992 Jul;51(1):197-
605	205. PMID: 1319114; PMCID: PMC1682892.

- 48. Vahdati Nia B, Kang C, Tran MG, Lee D, Murakami S. (2017) Meta Analysis of Human
  AlzGene Database: Benefits and Limitations of Using *C. elegans* for the Study of
  Alzheimer's Disease and Co-morbid Conditions. Front Genet. 2017 8:55. doi:
  10.3389/fgene.2017.00055. PMID: 28553317; PMCID: PMC5427079.
- 49. Weinert BT, Timiras PS. Theories of aging. J Appl Physiol. (2003) 95(4):1706-16. doi:
   10.1152/japplphysiol.00288.2003. PMID: 12970376.
- 50. Wufuer M, Fang MW, Cheng ZH, Qiu CC. (2004) [Polymorphism of angiotensin
  converting enzyme gene and natural longevity in the Xinjiang Uygur people: an
  association study]. Zhonghua Yi Xue Za Zhi. 84(19):1603-6. Chinese. PMID: 15569453.
- 51. Yang JK, Gong YY, Xie L, Lian SG, Yang J, Xu LY, Gao SJ, Zhang YP. (2009) Lack of genetic
  association between the angiotensin-converting enzyme gene insertion/deletion
  polymorphism and longevity in a Han Chinese population. J Renin Angiotensin
  Aldosterone Syst. 10(2):115-8. doi: 10.1177/1470320309104873. PMID: 19502260.
- 52. Zhang WF, Ling JH, Wang AJ. (2010) [Relationship between shen-deficiency syndrome
  and polymorphism of angiotensin converting enzyme gene in longevous elders in Bama
  area of Guangxi municipality]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 30(3):259-63. Chinese.
  PMID: 20535922.
- 53. Zintzaras E, Raman G, Kitsios G, Lau J. (2008) Angiotensin-converting enzyme
  insertion/deletion gene polymorphic variant as a marker of coronary artery disease: a
  meta-analysis. Arch Intern Med. 168(10):1077-89. doi: 10.1001/archinte.168.10.1077.
  PMID: 18504336.